Integra LifeSciences Holdings Co. (NASDAQ:IART) Receives Average Recommendation of "Reduce" from Analysts

Integra LifeSciences Holdings Co. (NASDAQ:IART - Get Free Report) has been assigned an average rating of "Reduce" from the eight ratings firms that are currently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $23.00.

A number of equities analysts have recently weighed in on IART shares. Citigroup increased their price target on Integra LifeSciences from $16.00 to $22.00 and gave the stock a "sell" rating in a report on Tuesday, November 5th. Morgan Stanley started coverage on Integra LifeSciences in a report on Monday, December 2nd. They set an "underweight" rating and a $20.00 price target for the company.

Integra LifeSciences Trading Down 4.1 %

Shares of IART traded down $0.90 during midday trading on Thursday, reaching $21.13. The company had a trading volume of 556,895 shares, compared to its average volume of 479,374. Integra LifeSciences has a 1-year low of $16.81 and a 1-year high of $45.11. The stock has a market cap of $1.63 billion, a PE ratio of -234.75, a price-to-earnings-growth ratio of 0.73 and a beta of 1.17. The firm has a 50 day simple moving average of $23.71 and a 200-day simple moving average of $21.81. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79.

Insider Activity

In other news, EVP Michael J. Mcbreen sold 1,700 shares of the firm's stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $24.16, for a total transaction of $41,072.00. Following the sale, the executive vice president now owns 56,182 shares of the company's stock, valued at approximately $1,357,357.12. This trade represents a 2.94 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 3.10% of the company's stock.

Institutional Investors Weigh In On Integra LifeSciences

Several hedge funds and other institutional investors have recently made changes to their positions in IART. Sachem Head Capital Management LP acquired a new stake in shares of Integra LifeSciences during the 3rd quarter worth about $44,153,000. Soleus Capital Management L.P. acquired a new position in Integra LifeSciences during the fourth quarter worth approximately $28,940,000. Paradigm Capital Management Inc. NY increased its position in Integra LifeSciences by 170.3% during the fourth quarter. Paradigm Capital Management Inc. NY now owns 1,431,100 shares of the life sciences company's stock worth $32,457,000 after buying an additional 901,600 shares during the period. Lord Abbett & CO. LLC increased its position in Integra LifeSciences by 86.8% during the fourth quarter. Lord Abbett & CO. LLC now owns 1,332,031 shares of the life sciences company's stock worth $30,210,000 after buying an additional 618,773 shares during the period. Finally, Glenmede Trust Co. NA increased its position in Integra LifeSciences by 125.9% during the third quarter. Glenmede Trust Co. NA now owns 727,781 shares of the life sciences company's stock worth $13,224,000 after buying an additional 405,624 shares during the period. Institutional investors and hedge funds own 84.78% of the company's stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.